About Cytochroma
Cytochroma is a company based in Bannockburn (Australia) founded in 1996 by Kate Cameron was acquired by Opko Health in January 2013.. Cytochroma has raised $74.03 million across 7 funding rounds from investors including Opko Health, BDC and Caisse de depot et placement du Quebec. Cytochroma operates in a competitive market with competitors including Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Alebund and Aurinia Pharmaceuticals, among others.
- Headquarter Bannockburn, Australia
- Founders Kate Cameron
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$74.03 M (USD)
in 7 rounds
-
Latest Funding Round
$1 M (USD), Series C
Jul 26, 2011
-
Investors
Opko Health
& 9 more
-
Employee Count
Employee Count
-
Acquired by
Opko Health
(Jan 08, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cytochroma
Cytochroma has successfully raised a total of $74.03M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $1 million completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $1.0M
-
First Round
First Round
(29 Oct 2001)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2011 | Amount | Series C - Cytochroma | Valuation |
investors |
|
| Jul, 2008 | Amount | Series C - Cytochroma | Valuation |
investors |
|
| Mar, 2007 | Amount | Series C - Cytochroma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cytochroma
Cytochroma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Opko Health, BDC and Caisse de depot et placement du Quebec. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage technology startups are supported through investments by MaRS IAF.
|
Founded Year | Domain | Location | |
|
Stage-agnostic sector-agnostic VC firm investing in Canada and the US
|
Founded Year | Domain | Location | |
|
Private equity buyouts are targeted by the investment firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cytochroma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cytochroma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytochroma Comparisons
Competitors of Cytochroma
Cytochroma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Alebund and Aurinia Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Therapeutics for renal diseases are developed and launched by Renalys.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Cytochroma
When was Cytochroma founded?
Cytochroma was founded in 1996 and raised its 1st funding round 5 years after it was founded.
Where is Cytochroma located?
Cytochroma is headquartered in Bannockburn, Australia. It is registered at Bannockburn, Victoria, Australia.
Is Cytochroma a funded company?
Cytochroma is a funded company, having raised a total of $74.03M across 7 funding rounds to date. The company's 1st funding round was a Series C of $3M, raised on Oct 29, 2001.
What does Cytochroma do?
Developer of therapeutics to treat secondary hyperparathyroidism (SHPT). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4, or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Who are the top competitors of Cytochroma?
Cytochroma's top competitors include Calliditas Therapeutics, Akebia Therapeutics and Gennova.
Who are Cytochroma's investors?
Cytochroma has 10 investors. Key investors include Opko Health, BDC, Caisse de depot et placement du Quebec, Mitsubishi Tanabe Pharma, and MaRS IAF.